A nanosystem for water-insoluble drugs prepared by a new technology, nanoparticulation using a solid lipid and supercritical fluid

Archives of Pharmacal Research

Volumn 36, Issue 11, 2013, Pages 1369-1376

  Park, Joo Won ^a,b   Yun, Jeong Min ^a   Lee, Eun Seong ^c   Youn, Yu Seok ^d   Kim, Kab Sig ^b   Oh, Young Taik ^e   Oh, Kyung Teak ^a  

^a Chung Ang University   (South Korea)

^b Bio Synectics Inc   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Yonsei University   (South Korea)

Author keywords

Insoluble drug; Itraconazole; Nanoparticle; NUFS; Solid dispersion; Supercritical fluid

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; ITRACONAZOLE; LIPID; MANNITOL; NANOPARTICLE; POLOXAMER; SUCROSE;

ARTICLE; CRYSTALLIZATION; DISPERSION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG SYNTHESIS; EMULSION; FREEZE DRYING; HYDROPHOBICITY; MEDICATION COMPLIANCE; MELTING POINT; NANOTECHNOLOGY; PARTICLE SIZE; PHYSICAL CHEMISTRY; POWDER; SOLUBILIZATION; SOLVENT EFFECT; SPRAY DRYING; SUPERCRITICAL FLUID; TABLET; VISCOSITY;

ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; ITRACONAZOLE; LIPIDS; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; SOLUBILITY; WATER;

EID: 84888137559     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0187-2     Document Type: Article

References (44)

1. Al-Marzouqui, A.; I. Shehatta, B. Jobe, and A. Dowaidar. 2006. Phase solubility and inclusion complex of itraconazole with β-cyclodextrin using supercritical carbon dioxide. Journal of Pharmaceutical Sciences 95: 292-304.
2. Allen, L.V.; R.S. Levinson, and D. De Martono. 1978. Dissolution rates of hydrocortisone and prednisone utilizing sugar solid dispersion systems in tablet form. Journal of Pharmaceutical Sciences 67: 979-981.
3. Arnum, P.V. 2010. Solubilizing the Insoluble. Pharmaceutical Technology 35: 50-56.
4. Benet, L.Z.; C. Wu, and J.M. Custodio. 2006. Predicting drug absorption and the effects of food on oral bioavailability. Bulletin Technology Gattefosse 99: 9-16.
5. Borm, P.; F. Klaessig, T. Landry, and E. Al. 2006. Research strategies for safety evaluation of nanomaterials, part V: Role of dissolution in biological fate and effects of nanoscale particles. Toxicol Science 90: 23-32.
6. Challa, R.; A. Ahuja, J. Ali, and R.K. Khar. 2005. Cyclodextrins in drug delivery: An updated review. AAPS PharmSciTech 6: E329-E357.
7. Chen, H.; C. Khemtong, X. Yang, X. Chang, and J. Gao. 2011. Nanonization strategies for poorly water-soluble drugs. Drug Discovery Today 16: 354-360.
8. Debord, B.; C. Lefebvre, A.M. Guyot-Hermann, J. Hubert, R. Bouche, and J.C. Cuyot. 1987. Study of different crystalline forms of mannitol: Comparative behaviour under compression. Drug Development and Industrial Pharmacy 13: 1533-1546.
9. Fahr, A.; and X. Liu. 2007. Drug delivery strategies for poorly water-soluble drugs. Expert Opinion on Drug Delivery 4: 403-416.
10. Foster, N.; R. Mammucari, F. Dehghani, A. Barrett, K. Bezanehtak, E. Coen, G. Combes, L. Meure, A. Ng, and H.L. Regtop. 2003. Processing pharmaceutical compounds using dense gas technology. Industrial and Engineering Chemistry Research 42: 6476-6493.
11. Horter, D.; and J.B. Dressman. 2001. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Advanced Drug Delivery Reviews 46: 75-87.
12. Jackson, K.; D. Young, and S. Pant. 2000. Drug-excipient interactions and their affect on absorption. Pharmaceutical Science and Technology Today 3: 336-345.
13. Kawabata, Y.; K. Wada, M. Nakatani, S. Yamada, and S. Onoue. 2011. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. International Journal of Pharmacy 420: 1-10.
14. Keck, C.M.; and R.H. Muller. 2006. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. European Journal of Pharmaceutics and Biopharmaceutics 62: 3-16.
15. Kesisoglou, F.; S. Panmai, and Y. Wu. 2007. Nanosizing-oral formulation development and biopharmaceutical evaluation. Advanced Drug Delivery Reviews 59: 631-644.
16. Kim, K.-S. (2007) Method for preparing nano-scale or amorphous particle using solid fat as a solvent. BIO-SNECTICS INC.; US 2007/0071826 A1, US.
17. Kim, K.; and Cho, Y. (2007) Method for preparing nano-scale particle of active material. Bio-Synectics, Inc. WO/2007/129829.
18. Kim, K.T.; J.Y. Lee, M.Y. Lee, C.K. Song, J. Choi, and D-.D. Kim. 2011. Solid dispersions as a drug delivery system. Journal of Pharmaceutical Investigation 41: 125-142.
19. Kipp, J.E. 2004. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. International Journal of Pharmaceutics 284: 109-122.
20. Ku, M.S.; and W. Dulin. 2012. A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept. Pharmaceutical Development and Technology 17: 285-302.
21. Löbenberg, R.; and G.L. Amidon. 2000. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. European Journal of Pharmaceutics and Biopharmaceutics 50: 3-12.
22. Lee, S.J.; Y.H. Kim, S.H. Lee, and M. Hahn. 2012. Characterization of nano oxaliplatin prepared by novel Fat Employing Supercritical Nano System, the FESNS(R). Pharmaceutical Development and Technology 17: 212-218.
23. Lindenberg, M.; S. Kopp, and J.B. Dressman. 2004. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. European Journal of Pharmaceutics and Biopharmaceutics 58: 265-278.
24. Lipinski, C.A. 2000. Drug-like properties and the causes of poor solubility and poor permeability. Journal of Pharmacological and Toxicological Methods 44: 235-249.
25. Lipinski, C.A.; F. Lombardo, B.W. Dominy, and P.J. Feeney. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 46: 3-26.
26. Liu, R. 2008. Water-insoluble drug formulation. Boca Raton: CRC Press.
27. Muller, R.H.; and K. Peters. 1998. Nanosuspensions for the formulation of poorly water soluble drugs. I. Preparation by a size reduction technique. International Journal of Pharmaceutics 160: 229-237.
28. Noyes, A.A.; and W.R. Whitney. 1897. The rate of solution of solid substances in their own solution. Journal of the American Chemical Society 19: 930-934.
29. Pasquali, I.; R. Bettini, and F. Giordano. 2008. Supercritical fluid technologies: An innovative approach for manipulating the solid-state of pharmaceuticals. Advanced Drug Delivery Reviews 60: 399-410.
30. Patel, D.V.; and E.M. Gordon. 1996. Applications of small-molecule combinatorial chemistry to drug discovery. Drug Discovery Today 1: 134-144.
31. Rabinow, B.E. 2004. Nanosuspensions in drug delivery. Nat Rev Drug Discov 3: 785-796.
32. Rambali, B.; G. Verreck, L. Baert, and D.L. Massart. 2003. Itraconazole formulation studies of the melt-extrusion process with mixture design. Drug Development and Industrial Pharmacy 29: 641-652.
33. Sastry, S.; J. Nyshadham, and J. Fix. 2000. Recent technological advances in oral drug delivery-a review. Pharmaceutical Science and Technology Today 3: 138-145.
34. Saxena, V.; R. Panicucci, Y. Joshi, and S. Garad. 2009. Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates. Journal of Pharmaceutical Sciences 98: 1962-1979.
35. Sekhon, B.S. 2010. Supercritical fluid technology: An overview of pharmaceutical applications. International Journal of PharmTech Research 2: 810-826.
36. Serajuddin, A.T.M. 2007. Salt formation to improve drug solubility. Advanced Drug Delivery Reviews 59: 603-616.
37. Sharma, P.; W.A. Denny, and S. Garg. 2009. Effect of wet milling process on the solid state of indomethacin and simvastatin. International Journal of Pharmaceutics 380: 40-48.
38. Stella, V.J.; and K.W. Nti-Addae. 2007. Prodrug strategies to overcome poor water solubility. Advanced Drug Delivery Reviews 59: 677-694.
39. Tao, L.; W. Hu, Y. Liu, G. Huang, B. Sumer, and J. Gao. 2011. Shape-specific polymeric nanomedicine: Emerging opportunities and challenges. Experimental Medicine and Biology 236: 20-29.
40. Torchilin, V. 2007. Micellar nanocarriers: Pharmaceutical perspectives. Pharmaceutical Research 24: 1-16.
41. Valizadeh, H.; A. Nokhodchi, N. Qarakhani, P. Zakeri-Milani, S. Azarmi, D. Hassanzadeh, and R. Lobenberg. 2004. Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, lactose, sorbitol, dextrin, and Eudragit E100. Drug Development and Industrial Pharmacy 30: 303-317.
42. Van Eerdenbrugh, B.; G. Van Den Mooter, and P. Augustijns. 2008. Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. International Journal of Pharmaceutics 364: 64-75.
43. Van Speybroeck, M.; R. Mols, R. Mellaerts, T.D. Thi, J.A. Martens, J.V. Humbeeck, P. Annaert, G.V.D. Mooter, and P. Augustijns. 2010. Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole. European Journal of Pharmaceutics and Biopharmaceutics 75: 354-365.
44. Westesen, K.; H. Bunjes, and M.H.J. Koch. 1997. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. Journal of Controlled Release 48: 223-236.